Corpus Intelligence IC Memo — DOUGLAS HOSPITAL 2026-04-26 04:05 UTC
IC Memo — DOUGLAS HOSPITAL
Investment Committee Memorandum | GA | 112 beds | Grade C | EBITDA uplift $16.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DOUGLAS HOSPITAL

CCN 110184 | DOUGLAS, GA | 112 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DOUGLAS HOSPITAL is a 112-bed suburban community hospital in DOUGLAS, GA with $217.2M in net patient revenue and a -0.8% operating margin. The hospital serves a payer mix of 21.2% Medicare, 8.9% Medicaid, and 69.9% commercial.

Thesis: Undervalued. Our ML models identify $16.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.8% to 6.5% (+736bps).

Net Revenue HCRIS$217.2M
Current EBITDA COMPUTED$-1.8M
Operating Margin COMPUTED-0.8%
Occupancy HCRIS78.8%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS16.4%
Distress Probability ML40.0%

2. Market Context & Competitive Position

165
GA Hospitals
-2.8%
State Median Margin
59
Comparable Hospitals

GA has 165 Medicare-certified hospitals with a median operating margin of -2.8%. The target's margin of -0.8% places it above the state median. Among 59 size-comparable peers (56-224 beds), the median margin is -3.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (56-224), prioritizing same-state peers. 59 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DOUGLAS HOSPITAL (Target)GA112$217.2M-0.8%
NORTHSIDE HOSPITAL-CHEROKEE IGA212$623.5M-0.1%
TIFT REGIONAL MEDICAL CENTERGA181$372.8M-10.9%
PIEDMONT NEWNAN HOSPITAL INC.GA177$366.0M19.2%
SOUTH GEORGIA MEDICAL CENTERGA224$359.9M-16.2%
HAMILTON MEDICAL CENTERGA221$349.6M5.3%
NORTH FULTON REGIONAL HOSPITALGA178$320.1M6.6%
TANNER MEDICAL CENTERGA196$307.5M-42.3%
ST. JOSEPHS HOSPITAL INC.GA188$300.6M-15.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $16.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.6M+210bp18mo
Cost to Collect4.5%2.5%$4.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.6M+122bp9mo
Clean Claim Rate88.0%96.0%$139K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.6M
Cost to Collect
$4.3M
Denial Rate Reduction
$4.3M
A/R Days Reduction
$2.6M
Clean Claim Rate
$139K
Total EBITDA Uplift$16.0M
Current EBITDA$-1.8M
+ RCM Uplift+$16.0M
Pro Forma EBITDA$14.2M
Current Margin-0.8%
Pro Forma Margin6.5%
WC Released (1x)$8.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.8M$148.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.8M$161.9M0.00x-100.0%
Bull Case9.0x11.0x$-2.5M$213.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.5M$232.5M0.00x-100.0%
Bear Case11.0x10.0x$-3.0M$69.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-3.0M$74.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 59 hospitals with 56-224 beds
  • Same-state prioritization (n=60)
  • Comp margins: P25=-12.0% / P50=-3.3% / P75=6.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.